MATERNAL BLOOD PRESSURE IN RELATION TO LOW BIRTH WEIGHT AND THE EFFECT OF A NUTRITIONAL SUPPLEMENT by Abreu, Alyssa
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2019 
MATERNAL BLOOD PRESSURE IN RELATION TO LOW BIRTH 
WEIGHT AND THE EFFECT OF A NUTRITIONAL SUPPLEMENT 
Alyssa Abreu 
University of Rhode Island, amabreu@uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Abreu, Alyssa, "MATERNAL BLOOD PRESSURE IN RELATION TO LOW BIRTH WEIGHT AND THE EFFECT 
OF A NUTRITIONAL SUPPLEMENT" (2019). Open Access Master's Theses. Paper 1456. 
https://digitalcommons.uri.edu/theses/1456 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 





MATERNAL BLOOD PRESSURE IN RELATION TO LOW BIRTH WEIGHT 






A THESIS SUBMITTED IN PARTIAL 
FULFILLMENT OF THE REQUIREMENTS FOR 
THE DEGREE OF MASTER OF SCIENCE  
IN 










   
 
 




















Major Professor Brietta Oaks 
 
   Ashley Buchanan 
 
   Ingrid Lofgren 
    
      Nasser H. Zawia 

















Background: Hypertensive disorders of pregnancy impact over 10% of pregnancies 
worldwide, while increasing the risk of low birth weight. Research is conflicting on 
the effect of nutrient supplementation on hypertension during pregnancy. The cutoffs 
to define hypertension have also recently changed to include a lower systolic blood 
pressure, and little research has examined the association between the newly proposed 
blood pressure cutoffs and low birth weight.  
Objectives: Our objectives were to 1) evaluate the impact of prenatal lipid-based 
nutrient supplement consumption on maternal blood pressure; and 2) assess the 
association between maternal blood pressure during early and late pregnancy with 
infant birth weight.  
Study Design: A total of 1320 pregnant women ≤ 20 weeks gestation in Ghana were 
randomized to receive daily either: 1) iron and folic acid, 2) multiple micronutrients, 
or 3) a small-quantity lipid-based nutrient supplement. Gestational age was determined 
by ultrasound and newborn weight measured at delivery. Blood pressure was 
measured at enrollment and 36 weeks gestation. The effect of the consumption of a 
lipid-based nutrient supplement on maternal blood pressure was analyzed using 
ANOVA and ANCOVA, and associations between maternal hypertension and birth 
weight were examined by linear and logistic regressions. 
Results: Mean (±SD) systolic and diastolic blood pressure at 36 weeks gestation were 
110±11 and 63±8 mmHg, respectively. The means for systolic and diastolic blood 
pressure did not differ by supplementation group, (p-value>0.05). The prevalence of 
high systolic blood pressure (≥ 130 mmHg) and high diastolic blood pressure (≥ 80 
   
 
 
mmHg) at enrollment was 6.6% and 3.6% and there was a significant association 
between higher diastolic blood pressure and lower birth weight at enrollment (! = -
0.086, SE = 0.001 ; p = 0.011) in adjusted models. High diastolic blood pressure 
significantly increased the risk for low birth weight (odds ratio  = 2.99, 95% 
confidence interval 1.04-8.62; p=0.042) in adjusted models. At 36 weeks, the 
prevalence of high systolic and high diastolic blood pressure was 4.3% and 2.4% and 
lower birth weight was significantly associated with higher systolic (! = -0.074, SE = 
0.00 ; p = 0.029) and diastolic (! =  -0.094, 0.00; p = 0.006) blood pressure. Diastolic 
blood pressure was significantly associated with an increased risk of low birth weight 
(OR=4.14, 95% CI=0.020). 
Conclusions:  Daily consumption of a lipid-based nutrient supplement during 
pregnancy did not have a significant effect on maternal hypertension compared with 
iron and folic acid or multiple micronutrients among women in Ghana. Both higher 
systolic and higher diastolic blood pressure were associated with a lower birth weight, 
although the association of diastolic blood pressure was larger in magnitude. Due to 
the high rates of hypertension during pregnancy it is necessary to determine effective 
strategies for prevention. Maternal hypertension may have implications for newborn 
birth weight, and future research should determine blood pressure cutoffs specific to 
pregnant populations that effectively identify pregnancies at risk for newborn low 
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Condensation: There was no significant effect of consumption of a lipid-based 
nutrient supplement on hypertension during pregnancy. Maternal hypertension was 
associated with newborn birth weight.  
Short Title: Maternal BP in Relation to Birth Weight and the Effect of a Nutrient 
Supplement 
AJOG at a Glance: 
A.  Due to recent changes in blood pressure cut-offs, it remains unknown whether 
prenatal lipid-based nutrient supplements affect blood pressure or whether 
maternal hypertension is associated with newborn birth weight.  
B. Adherence to a nutritional supplement was not associated with blood pressure, 
and maternal hypertension was associated with birth weight.  
C. Both high diastolic and high systolic blood pressure were significantly 










Background: Hypertensive disorders of pregnancy impact over 10% of pregnancies 
worldwide, while increasing the risk of low birth weight. Research is conflicting on 
the effect of nutrient supplementation on hypertension during pregnancy. The cutoffs 
to define hypertension have also recently changed to include a lower systolic blood 
pressure, and little research has examined the association between the newly proposed 
blood pressure cutoffs and low birth weight.  
Objectives: Our objectives were to 1) evaluate the impact of prenatal lipid-based 
nutrient supplement consumption on maternal blood pressure; and 2) assess the 
association between maternal blood pressure during early and late pregnancy with 
infant birth weight.  
Study Design: A total of 1320 pregnant women ≤ 20 weeks gestation in Ghana were 
randomized to receive daily either: 1) iron and folic acid, 2) multiple micronutrients, 
or 3) a small-quantity lipid-based nutrient supplement. Gestational age was determined 
by ultrasound and newborn weight measured at delivery. Blood pressure was 
measured at enrollment and 36 weeks gestation. The effect of the consumption of a 
lipid-based nutrient supplement on maternal blood pressure was analyzed using 
ANOVA and ANCOVA, and associations between maternal hypertension and birth 
weight were examined by linear and logistic regressions. 
Results: Mean (±SD) systolic and diastolic blood pressure at 36 weeks gestation were 
110±11 and 63±8 mmHg, respectively. The means for systolic and diastolic blood 
pressure did not differ by supplementation group, (p-value>0.05). The prevalence of 
high systolic blood pressure (≥ 130 mmHg) and high diastolic blood pressure (≥ 80 
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mmHg) at enrollment was 6.6% and 3.6% and there was a significant association 
between higher diastolic blood pressure and lower birth weight at enrollment (! = -
0.086, SE = 0.001 ; p = 0.011) in adjusted models. High diastolic blood pressure 
significantly increased the risk for low birth weight (odds ratio  = 2.99, 95% 
confidence interval 1.04-8.62; p=0.042) in adjusted models. At 36 weeks, the 
prevalence of high systolic and high diastolic blood pressure was 4.3% and 2.4% and 
lower birth weight was significantly associated with higher systolic (! = -0.074, SE = 
0.00 ; p = 0.029) and diastolic (! =  -0.094, 0.00; p = 0.006) blood pressure. Diastolic 
blood pressure was significantly associated with an increased risk of low birth weight 
(OR=4.14, 95% CI=0.020). 
Conclusions:  Daily consumption of a lipid-based nutrient supplement during 
pregnancy did not have a significant effect on maternal hypertension compared with 
iron and folic acid or multiple micronutrients among women in Ghana. Both higher 
systolic and higher diastolic blood pressure were associated with a lower birth weight, 
although the association of diastolic blood pressure was larger in magnitude. Due to 
the high rates of hypertension during pregnancy it is necessary to determine effective 
strategies for prevention. Maternal hypertension may have implications for newborn 
birth weight, and future research should determine blood pressure cutoffs specific to 
pregnant populations that effectively identify pregnancies at risk for newborn low 
birth weight.  
Keywords: Ghana, low birth weight, maternal blood pressure, nutrient supplements, 
pregnancy outcomes, prenatal supplementation 
 




During a healthy pregnancy, blood pressure decreases from early to mid-
pregnancy, increases in late pregnancy, and then returns to pre-pregnancy levels by 
delivery.1 However, during pregnancy blood pressure may not change as expected, but 
gradually rise and result in hypertension (HTN). HTN is defined as a systolic blood 
pressure (SBP)  ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 80 mmHg.2 The 
definition was recently updated by the American Heart Association from an SBP ≥ 
140 mmHg or DBP ≥ 80 mmHg due to the increased risk for cardiovascular disease in 
the general population.2 It is unclear if the new definition is appropriate for predicting 
pregnancies at risk of adverse outcomes.  
Ghana is a low-middle income country located in western Africa.  Based on the 
previous HTN cutoffs, over 20% of pregnancies in Ghana are impacted by HTN,3 
compared to about 10% worldwide.4 The disparity may be related to lack of access to 
adequate health care, a delay in seeking health care, or delayed response to maternal 
health status at the health care facilities.5   
Hypertensive disorders of pregnancy have been associated with increased risk for 
low birth weight (LBW),6 which is defined as a newborn birth weight of  < 2500 
grams. LBW is associated with infections7 and trouble breathing8 for the infant, as 
well as increased risk for diabetes and obesity,9 and intellectual and developmental 
disabilities.10  
 Nutritional supplements may be an effective strategy to decrease the risk for 
maternal HTN, especially since anti-hypertensive medication may increase the risk for 
pregnancy complications.11, 12 Calcium supplementation daily has been associated with 
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a decreased risk of maternal HTN, although evidence supports calcium 
supplementation as only protective against HTN for women with low calcium intake.13 
There is emerging evidence that lipids, specifically essential fatty acids (EFA), may 
play a role in decreasing placental dysfunction and inflammation, and support 
increased fetal growth.14, 15 However, EFAs have been associated with reduced risk of 
maternal HTN and inflammatory markers only in animal studies. Larger intervention 
studies in women have not found significant associations between EFA 
supplementation or intake and maternal HTN.16 Research on nutrient supplementation 
including EFAs that may decrease the risk of maternal HTN in human populations is 
needed.  
 Our objectives were to 1) evaluate the impact of prenatal lipid-based nutrient 
supplement (LNS) consumption on maternal blood pressure; and 2) assess the 
association between maternal HTN during early and late pregnancy and newborn birth 
weight using the new blood pressure cutoffs. 
 
MATERIALS AND METHODS 
Study Design  
This is a secondary data analysis of the International Lipid-Based Nutrient 
Supplements (iLiNS) Project; a randomized controlled trial. The research team 
recruited pregnant women attending select prenatal clinics in the Eastern region of 
Ghana, to determine the effects of nutrient supplements during pregnancy and the first 
eighteen months of the newborn’s early childhood. For this analysis, data collected 
from early pregnancy through birth will be used. LNS is a paste designed to be mixed 
 
 8  
 
 
with local foods, such as maize, cassava, rice, fish, and leafy vegetables, to increase 
the nutrient and energy content for enrolled Ghanaian women during pregnancy and 
lactation. Multiple micronutrient (MMN) and LNS supplements followed formulations 
for United Nations Micronutrient Preparation (UNIMAP) previously used for prenatal 
micronutrient supplementation in pilot programs among pregnant women.17 Nutriset 
S.A.S. (Malaunay, France) produced the LNS in 20g sachets and Dutch State Mines 
(DSM) South Africa (Kaiseraugst, Switzerland) produced the capsules of the iron and 
folic acid (IFA) and MMN supplements. A more detailed description of the study 
population and methods have previously been described.18  
The iLiNS study protocol was approved by the institutional review boards at 
the University of California, Davis; the Noguchi Memorial Institute for Medical 
Research, University of Ghana; and the Ghana Health Service. 
Participants 
 Eligibility for this study was specific to women attending prenatal clinics in 
southern Ghana between December 2009 through December 2011, an age of at least 
18 years old, and a gestational age of ≤ 20 weeks. Reasons for exclusion included a 
test result that was HIV positive at baseline, a gestational age > 20 weeks, residence > 
20 km outside of southern Ghana, history of peanut or milk allergies, severe illness, or 
the intention to move within two years. Participants consented to screen for eligibility, 
and if eligible, fieldworkers collected anthropometrics and baseline lab values.   
 A randomization scheme was designed by a study statistician. Each woman 
was randomized into either the IFA, MMN, or LNS group. To ensure blinding, an 
independent party from the research team color-coded supplement capsules of the IFA 
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and MMN groups to blind investigators, fieldworkers, and participants. Fieldworkers 
were not aware of the group allocations, and data analysts were blinded until the 
completion of preliminary analyses 
Procedures 
At enrollment, the research group distributed surveys to participants and 
collected demographic characteristics and lab data. The research group collected lab 
data again at 36 weeks gestation and newborn anthropometric measurements at 
delivery.  
At enrollment, fieldworkers distributed a two week supply of the assigned 
supplement along with instructions on consumption methods. At bi-weekly, in-home 
follow-ups with each participant, data on supplement adherence and morbidity, as well 
as any remaining supplement were collected. Fieldworkers visited the home or 
hospital at delivery to collect anthropometric measurements of newborns. For 91% of 
infants, measurements were recorded within 48hrs of birth. Measurements for 9% of 
infants were not available after 48hrs, and so measurements were collected between 3-
14 days after birth.  
Primary Outcomes and Definitions  
Our primary outcomes to determine the effect of a nutrition supplement on 
maternal hypertension are mean SBP and mean DBP at enrollment and 36 weeks 
gestation. Our primary outcome to determine the association between maternal HTN 
and birth weight is mean newborn birth weight. High SBP was defined as ≥130 mmHg 
and high DBP as ≥80 mmHg. Consistent with the iLiNS study, for age- and sex-
standardization of blood pressure and weight, the WHO 2006 multi-center growth 
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standard was used.19 If the baby was measured within 48 hours, birth weight is 
reported in grams. If after 48 hours, adjustments for weight following the main iLiNS 
study were employed. 
Statistical Analysis - Effect of LNS on Maternal HTN  
In this randomized study design, quantifying the as-treated effect of LNS on 
maternal hypertension was of primary interest. During the study, IFA and MMN 
capsules were unintentionally mislabeled, causing 92 participants in the IFA group 
and 85 participants in the MMN group to receive the incorrect supplement. Therefore, 
this analysis used the supplement treatment assignment actually received and not the 
treatment originally assigned. A total of 86 women not-exposed in the LNS group, as 
well as the mixed-exposure women in the IFA or MMN groups were excluded.   
The main iLiNS trail included a total sample size of 1,057 (excluding women 
pregnant during mixed exposure), where IFA = 349, MMN = 354, and LNS = 354. 
Our sample size for each group is consistent with the main iLiNS trial and included 
the total sample size of 1,057. All tests were two-sided, at a 5% level of significance.  
Residuals were assessed for normality using a Shapiro-Wilk statistic. Pre-
pregnancy body mass index (BMI), C-reactive protein (CRP) at enrollment, and α1-
acid glycoprotein (AGP) at enrollment were not normally distributed and were 
logarithmically transformed for analysis. The heteroscedasticity assumption was also 
examined through the plots and no outliers were identified through visual 
identification in histograms or scatterplots.  
Variables that were possible confounds and had a statistically significant 
association with the outcome (p<0.1 in univariate models) were included in an 
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adjusted regression model. To avoid collinearity, variables were considered in the 
separate logistic regression models to assess the effect of the intervention on maternal 
blood pressure. If a variable was significantly associated with the effect of the 
intervention, logistic regression was used to determine if the effect of LNS on blood 
pressure was significantly different between groups. The null-hypothesis was rejected 
at the 0.05 level.  
Linear regression was used to estimate the study intervention effects on blood 
pressure.  For the continuous outcomes, the difference between the three group means 
was tested with ANOVA and ANCOVA models. If the null-hypothesis was rejected at 
the 0.05 level, post-hoc pairwise comparisons across the three intervention groups was 
tested using the Benjamini-Hochberg procedure to adjust for multiple comparisons.20  
Due to the number of participants exposed to the incorrect supplement, a 
sensitivity analysis was conducted to determine if the exclusion of those women 
influenced the results. The analyses determining the effect of LNS on maternal HTN 
was repeated with all participants included.  
Statistical Analysis - Association Between Maternal HTN and Birth Weight  
We evaluated normality of the residuals using a Shapiro-Wilk statistic. The 
distributions of pre-pregnancy BMI, CRP and AGP at enrollment had deviations from 
normality, and were logarithmically transformed for analysis. The heteroscedasticity 
assumption was examined through the residual versus fit plot. A scatterplot between 
the independent and dependent variables was visually examined to check that the 
relationship between the predictor and response was linear. No outliers were visually 
identified through histograms or scatterplots.   
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The covariates recorded at enrollment that had a statistically significant 
association with the outcome (p<0.1) were included in adjusted regression models. For 
continuous predictors, collinearity was checked by running models with covariates and 
an examination of variance inflation factors (VIF). VIF above 10 was considered 
problematic, however, there were no variables that exceeded a VIF of two. Therefore, 
there was no evidence of collinearity and all variables significantly associated with the 
outcome were included in adjusted models.  
Continuous variables were analyzed with linear regression if they were 
determined to have a statistically significant association with the outcome. Multiple 
linear regression models were used to determine the association between systolic and 
diastolic blood pressure and birth weight.  
 
RESULTS 
The total sample size used in this analysis included 1,057 pregnant women, 
with a 19% loss to follow up. There were 349 women included in the IFA group, 354 
in MMN and 354 included in the LNS group. Means (±#$)	and percentages of 
maternal characteristics at enrollment for the IFA, MMN and LNS groups are shown 
in Table 2, as well as the geometric mean and 95% confidence interval (CI) for CRP 
and AGP. The prevalence of HTN at 36 weeks gestation was 5.3% (SBP ≥ 130 mmHg 
or DBP ≥ 80 mmHg). The prevalence of high SBP at 36 weeks gestation was 4.3% 
and high DBP was 2.4%.  
Supplement Group Comparisons 
Table 3 shows the mean SBP and DBP at 36 weeks gestation by supplement 
group. The unadjusted and adjusted means of SBP and DBP at 36 weeks gestation 
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were not significantly different between groups (p>0.05). Maternal age modified the 
effect of the intervention on maternal SBP at 36 weeks; F(2, 1054) = 3.40, (p-value for 
interaction = 0.034). Maternal age was categorized into high and low age groups using 
the median, and the effect of the intervention on maternal SBP at 36 weeks was no 
longer significant, F(2,1054) = 1.40, (p-interaction = 0.246). There were no significant 
differences in risk for maternal HTN between IFA or MMN and LNS (table 4).   
In the sensitivity analysis including all women (exposed and not exposed) 
neither SBP or DBP means significantly differed by supplementation group in 
unadjusted or adjusted analysis.  
Maternal BP and Newborn Birth Weight. 
Table 5 presents the characteristics of total, normal, and HTN groups at 
enrollment. Women with HTN had a significantly higher age, pre-pregnancy BMI, 
height, SBP and DBP compared to those with normal blood pressure; (p<0.05).  
At enrollment, SBP was not significantly associated with a lower birth weight 
in unadjusted or adjusted models determining standardized beta (!) coefficients (table 
6). Similarly, high SBP did not significantly increase the risk for LBW (Table 7).  
However, as opposed to SBP, DBP at enrollment was significantly associated with a 
lower birth weight in adjusted models and remained significant after the Benjamini-
Hochberg procedure (! = -0.086, SE = 0.001 ; p = 0.011). High DBP at enrollment 
significantly increased the risk for LBW (odds ratio (OR) = 2.99, 95% confidence 
interval (95% CI)= 1.04-8.62; p=0.042) when adjusting for pre-pregnancy BMI, 
maternal age, height, assets index, parity, hemoglobin, offspring sex, and treatment 
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group, SBP and DBP at enrollment. However, after the Benjamini-Hochberg 
Procedure it was no longer statistically significant (p=0.064).  
Unlike early pregnancy, at 36 weeks gestation, higher SBP was significantly 
associated with a lower birth weight in adjusted models (! = -0.074, SE = 0.00 ; p = 
0.029). High SBP did not significantly decrease the risk for LBW (OR=2.19, 95% CI 
=0.72-6.73; p=0.170). Higher DBP was significantly associated with a lower infant 
birth weight (! = -0.094, SE = 0.00 ; p = 0.006) and increased the risk of LBW to over 
four times the risk of those with normal blood pressure (OR=4.14, 95% CI=0.020).  
  
DISCUSSION 
In this study, higher DBP presented a strong association with lower newborn 
birth weight at enrollment and 36 weeks gestation. SBP was only significantly 
associated with a lower birth weight at 36 weeks gestation, and only DBP significantly 
decreased the risk for LBW. LNS did not significantly decrease the risk for maternal 
hypertension compared to IFA or MMN.   
The association between higher DBP and a lower birth weight, and LNS not 
significantly decreasing maternal blood pressure is consistent with previous research 
using the previous blood pressure cutoffs. In a study by Bakker et al. (2011), higher 
DBP had stronger associations with a lower birth weight compared to SBP, as well as 
an increased risk for LBW.21  A randomized control trial conducted in Bangladesh 
found no significant associations between LNS and maternal blood pressure.22  
Our findings that HTN is associated with LBW may be explained by maternal 
HTN leading to reduced placental perfusion,23 placental dysfunction, and increased 
inflammation.14  Inflammation may lead to fetal hypoxia that may inhibit fetal growth, 
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and thereby reduce newborn birth weight.24 Alternatively, maternal HTN may actually 
be a consequence of fetal growth restriction, as fetal growth restriction and placental 
dysfunction may decrease placental vasodilators, which are increasingly important 
during late pregnancy for blood pressure maintenance.25 The underlying mechanisms 
for how maternal blood pressure and birth weight are related remains unclear. 
The functional differences between DBP and SBP may explain our findings 
that DBP and SBP presented different associations with lower birth weight. DBP is 
largely responsible for cardiac output 26 and the amount of blood flow that the placenta 
and ultimately fetus may have access to.25  With increased DBP, there is decreased 
cardiac output, leading to decreased blood flow to the placenta, resulting in less fetal 
access to oxygen and nutrients required for growth.26  
 There are strengths and limitations of this study. Limitations to note include 
missing information related to the use of anti-hypertensive medications, which may 
affect newborn birth weight.  However, we were able to control for all women with a 
history of HTN prior to pregnancy, which would include those with a history of taking 
anti-hypertensive medication. That analysis examined women as a cohort, therefore, 
we are unable to attribute the causation of LBW to maternal HTN. This study also has 
many strengths including a low loss to follow-up and the reliability of methods. 
Specifically, ultrasound scans were used to determine gestational age, and both blood 
pressure measurements and newborn birth weight were measured by trained 
fieldworkers.   
Due to the high rates of HTN during pregnancy and considering the health 
disparities that exist in developing countries, it is necessary to determine effective 
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strategies for prevention. Research determining the effect of essential fatty acid 
supplementation on maternal HTN in human populations is needed. Maternal HTN 
may have implications for newborn birth weight, and future research should determine 
blood pressure cutoffs specific to pregnant populations that effectively identify 
pregnancies at risk for newborn LBW. 
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Table 1: Composition of supplements given to pregnant Ghanaian women recruited 
between 2009-2011 in the International Lipid-Based Nutrient Supplements (iLiNS) 
Project Study.  
 
Nutrient IFA MMN LNS 
Ration, g/d  1 tablet 20 
Total Energy, kcal  0 118 
Protein, g  0 2.6 
Fat, g  0 10 
Linoleic acid, g  0 4.59 
a-Linolenic acid, g  0 0.59 
Vitamin A, 'g RE  800 800 
Vitamin C, mg  100 100 
Vitamin B-1, mg  2.8 2.8 
Vitamin B-2, mg  2.8 2.8 
Niacin, mg  36 36 
Folic acid, 'g 400 400 400 
Pantothenic acid, mg  7 7 
Vitamin V-6, mg  3.8 3.8 
Vitamin B-12, 'g  5.2 5.2 
Vitamin D, IU   400 400 
Vitamin E, mg  20 20 
Vitamin K, 'g  45 45 
Iron, mg 60 20 20 
Zinc, mg  30 30 
Copper, mg  4 4 
Calcium, mg  0 280 
Phosphorus, mg  0 190 
Potassium, mg  0 200 
Magnesium, mg  0 65 
Selenium, 'g  130 130 
Iodine, 'g  250 250 
Manganese, mg  2.6 2.6 
 
Iron and folic acid (IFA capsule is standard practice and follows WHO and Ghana 
Health Service recommendation; multiple micronutrient supplement (MMN) capsule; 
lipid-based nutrient supplement (LNS) for pregnant and lactating women  
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Table 2: Characteristics at enrollment of pregnant Ghanaian women enrolled in the 









Maternal Age 26.5 (5) 26.9 (6) 26.5 (5) 
Gestational 
Age 16.3 (3) 16.2 (3) 16.22 (3) 
Parity    
Parous 62% 69% 64% 
BMI 24.5 (4) 24.4 (4) 24.7 (4) 




7.6 (4) 7.5 (4) 7.7 (4) 
Married or 
Cohabitating 92% 94% 93% 
Offspring Sex    
Female 49% 51% 49% 
CRP* 3.8 (3.3-4.3) 3.13 (2.78-3.52) 3.32 (2.92-3.79) 
AGP* 0.6 (0.6-0.7) 0.6 (0.6-0.6) 0.6 (0.6-0.6) 
Mean SBP 112 (10) 111 (12) 112 (11) 
Mean DBP 63 (7) 64 (8) 64.33 (8) 
Positive 
Malaria test 9% 8% 11% 
*Geometric mean and 95% Cl presented 
 
Abbreviations: IFA, iron and folic acid: capsule is standard practice and follows WHO 
and Ghana Health Service recommendation; MMN, multiple micronutrient 
supplement capsule; LNS, lipid-based nutrient supplement for pregnant and lactating 
women; BMI, body mass index; CRP, C-reactive protein; AGP, α1-acid glycoprotein; 






 24  
 
 
Table 3: Mean systolic and diastolic blood pressure at 36 weeks gestation by 
supplement group in pregnant Ghanaian women of International Lipid-Based Nutrient 











































Abbreviations: IFA, iron and folic acid: capsule is standard practice and follows WHO 
and Ghana Health Service recommendation; MMN, multiple micronutrient 
supplement capsule; LNS, lipid-based nutrient supplement for pregnant and lactating 
women; SBP, systolic blood pressure; DBP, diastolic blood pressure.  
Adjusted models included pre-pregnancy BMI, gestational age, maternal age, 
completed years of education, asset index, food insecurity index, hemoglobin status, 
maternal height, CRP, AGP, parity, history of hypertension, and malaria status; all 








Table 4: Adjusted odds of high systolic or diastolic blood pressure at 36 weeks 
gestation by supplement group in pregnant Ghanaian women of International Lipid-
Based Nutrient Supplements (iLiNS) Project Study 
 
 IFA vs LNS      MMN vs LNS 
  OR        95% CI       OR        95% CI 
Normal BP 1.00 - 1.00 - 
High SBP (n=45) 0.63 0.27-1.47 0.87 0.40-1.91 
High DBP (n=25) 0.56 0.19-1.67 0.93 0.33-2.61 
 
Abbreviations: IFA, iron and folic acid: capsule is standard practice and follows WHO 
and Ghana Health Service recommendation; MMN, multiple micronutrient 
supplement capsule; LNS, lipid-based nutrient supplement for pregnant and lactating 
women; SBP, systolic blood pressure; DBP, diastolic blood pressure.  
Adjusted models included pre-pregnancy BMI, gestational age, maternal age, 
completed years of education, asset index, food insecurity index, hemoglobin status, 
maternal height, CRP, AGP, parity, history of hypertension, and malaria status; all 
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Table 5: Characteristics of total, normal, and high blood pressure groups at enrollment 
of pregnant Ghanaian women of the International Lipid-Based Nutrient Supplements 














Mean (SD) or 
% p 
Maternal Age 26.7 (5) 26.6 (5) 28.6 (6) 0.007 
Gestational Age 16.2 (3) 16.2 (3) 16.3 (3) 0.857 
Parity    0.190 
Parous 65% 65% 73%  
BMI 24.5 (4) 24.3 (4) 28.6 (6) <0.001 
Height 158.9 (6) 158.8 (6) 160.5 (6) 0.023 
Education, 
completed years 
7.6 (3)  7.6 (4)  7.7 (4)  0.833 
Married or 
cohabitating 
93%  93% 93% 0.989 
Offspring Sex    0.496 
Female 50%  50% 45%  
CRP 3.39 (3.2-3.7) 3.36 (3.1-3.6) 4.75 (3.4-6.6) 0.092 
AGP 0.6 (0.6-0.6)  0.6 (0.6-0.6) 0.7 (0.6-0.7)  0.089 
SBP 112 (11)  110 (10) 135 (9)  <0.001 
DBP  64 (8) 63 (7)  80 (8) <0.001 
Positive Malaria 
test 
10% 10% 10% 0.782 
*Geometric mean and 95% Cl presented 
Abbreviations: BMI, body mass index; CRP, C-reactive protein; AGP, α1-acid 
glycoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood 
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Table 6: Unadjusted and adjusted beta (!) coefficients of systolic and diastolic blood 
pressure predictors at enrollment and  36 weeks gestation and newborn birth weight in 
the International Lipid-Based Nutrient Supplements (iLiNS) Project Study. 
Birth Weight, g 
! (SE) 
 Unadjusted Adjusted  
BP at Enrollment   
SBP (mmHg) 0.056 (0.001) -0.062 (0.001) 
p 0.087 0.066 
DBP (mmHg) 0.039 (0.001) -0.086 (0.001) 
p 0.230 0.011* 
   
BP at 36wks   
SBP (mmHg) 0.054 (0.001) -0.074 (0.001) 
p 0.101 0.029* 
DBP (mmHg) 0.043 (0.001) -0.094 (0.001) 
p 0.192 0.006* 
*significant after Benjamini-Hochberg procedure 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood 
pressure. p = p-value at 0.05 significance level.  
Adjusted models included pre-pregnancy BMI, maternal age, asset index, parity, 
hemoglobin status, offspring sex, maternal height, and treatment group; all covariates 
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Table 7. Adjusted odds of low birth weight (LBW) predicted by maternal blood 
pressure (BP) at enrollment an 36 weeks gestation in the International Lipid-Based 




OR                 95% CI                p 
BP at Enrollment    
Normal BP  
      (n=987) 1.00 - - 
High SBP 
(n=70) 1.04 0.35-3.06 0.948 
High DBP  
(n=38) 2.99 1.04-8.62 0.042† 
BP at 36wks     
Normal BP 
      (n=1012) 1.00 - - 
High SBP 
(n=45) 2.19 0.72-6.73 0.170 
High DBP  
(n=25) 4.14 1.26-13.62 0.020* 
*significant after Benjamini-Hochberg procedure  
†not significant after Benjamini-Hochberg procedure 
 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood 
pressure; normal SBP < 130mmHg; high SBP ≥ 130 mmHg; normal DBP < 80mmHg; 
high DBP ≥ 80 mmHg; LBW, low birth weight – infant born < 2500 grams.  
Adjusted models included pre-pregnancy BMI, maternal age, asset index, parity, 










REVIEW OF LITERATURE 
Introduction 
Over 10% of pregnancies are impacted by high blood pressure (HTN)1 which 
is currently defined as systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood 
pressure (DBP) ≥ 80 mmHg.2 Maternal HTN is associated with adverse pregnancy and 
birth outcomes, including increased risk for chronic disease and an infant born with a 
low birth weight (LBW). 3 To reduce the prevalence of HTN in pregnant populations, 
current nutrient recommendations are limited to an increase of dietary calcium to one 
gram daily, with conflicting evidence related to the effect of supplementing additional 
nutrients to decrease maternal blood pressure.4 
There are various disorders during pregnancy related to high blood pressure, 
including preeclampsia (PE), gestational hypertension (GH), and chronic 
hypertension. PE is a hypertensive disorder of pregnancy that includes proteinuria, in a 
previously normotensive woman.5 GH is an SBP ≥ 130 mmHg or DBP ≥ 80 mmHg 
recorded on two separate occasions during pregnancy or after 20 weeks gestation. 
Chronic hypertension is diagnosed prior to pregnancy or before 20 weeks gestation.  
Maternal Blood Pressure 
Blood pressure fluctuations during pregnancy are normal and expected.6 On 
average, in normal pregnancies, SBP decreases to 112 mmHg, and DBP decreases to 
65 mmHg by 12 weeks gestation.6 By late pregnancy, around 37 weeks gestation, both 
SBP and DBP increase to 116 and 70 mmHg.6,7 These fluctuations in blood pressure 
result from the blood supply requirements for normal development of the fetus,8,9 as 
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well as hormonal influences on vascular remodeling .10,11 However, there are many 
risk factors for maternal HTN. Among others, risk factors for maternal HTN include 
maternal age,12 chronic hypertension and a history of preeclampsia.13  
Maternal HTN is associated with complications during pregnancy as well an 
increased risk for long-term chronic disease. The overall risk for maternal mortality 
increases, as well as an increase in risk for maternal morbidity; specifically, the risks 
for cardiovascular disease, kidney disease, diabetes and chronic hypertension is 
increased.14-18 Maternal HTN significantly increases the risk (or hazard) by 44% to 
300% for ischemic heart disease, myocardial infarcts, myocardial infarct death, heart 
failure, ischemic stroke, kidney disease, and diabetes mellitus.14 Although maternal 
HTN factors may be related to pre-pregnancy cardiovascular risk factors,19 there are 
significant associations between hypertensive disorders of pregnancy and 
cardiovascular risk factors, including a greater BMI, higher SBP and DBP, and 
elevated levels of insulin and triglycerides.20  
A strategy to decrease maternal HTN includes the use of antihypertensive 
medication, although it is recommended that antihypertensive medication should only 
be prescribed with an SBP ≥ 160 mmHg or DBP ≥ 110 mmHg due to increased risk 
for pregnancy complications.21,22 This is in part due to the fact that all drugs for the 
treatment of high blood pressure during pregnancy cross the placenta.23 The 
consequences of this may include uteroplacental perfusion and maternal 
hepatotoxicity.24 The American Heart Association also specifically discourages the 
use of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin II receptor 
blockers (ARB) due to their association with adverse fetal and birth outcomes.25-27 
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However, despite recommendations, antihypertensive medication is increasingly being 
relied upon during pregnancy.28 For instance, in a review of antihypertensive 
medication use during pregnancy in a Medicaid population, the overall use increased 
almost 50% within six years, resulting in nearly 5% of pregnancies ultimately exposed 
to antihypertensive medication. Furthermore, participants were unlikely to switch to 
recommended antihypertensive medications, and continued with medications 
associated with increased risk for adverse outcomes.28 
The prevalence and impact of high maternal blood pressure may impact 
developing countries to a greater degree than developed countries. To be specific, in 
Ghana, over 19% of pregnancy-related deaths are related to hypertensive disorders of 
pregnancy,29 compared to the 7.4% in the United States.30 The disparity may be 
related to lack of access to or a delay in seeking health care, or delayed response to 
maternal health status at the health care facilities.31 In developing countries, there may 
also be limited ability to screen for hypertensive disorders, specifically in rural 
settings.32 Additionally, in Ghana it is estimated that nearly 43% of Ghanaian adults 
are obese, with an estimated 27.8% of women being overweight and 21.9% obese.33 
With this in mind, a cohort study conducted in Ghana by Amoakoh-Coleman et al. 
(2017),34 determined that women who were obese had three times the risk of 
gestational hypertension compared to pregnant women with a normal BMI (RR 3.01, 
95% CI: 1.06 – 8.52; p=0.04). However, this study had many limitations in that weight 
was not based on pre-pregnancy weight, but was measured at 20 weeks gestation. 
Another limitation was that women were excluded from the study if they were 
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previously diagnosed with hypertension at baseline; this may result in an 
underestimation of the risk of gestational hypertension. 
The underlying mechanisms for causes of maternal HTN remains unclear; 
however, hypertensive disorders of pregnancy may result from reduced uterine 
perfusion, placental dysfunction, genetic polymorphisms, and immune 
maladaptation,35 as well as their relationship with endothelial dysfunction. In animal 
studies, there is also evidence that a reduction of uterine perfusion pressure influences 
the distribution of a peptide receptor produced by the vascular endothelium, 
endothelin receptor type-B, which decreases vasodilatation and enhances 
vasoconstriction.36 Decreases in vasodilatation and enhanced vasoconstriction will 
increase the arterial pressure through increased arterial resistance resulting in an 
increased blood pressure. For PE specifically, abnormal uteroplacental blood 
circulation may lead to maternal endothelial dysfunction, ultimately resulting in 
maternal HTN and proteinuria.37 In addition, increased inflammatory markers 
including C-reactive protein, tumor necrosis factor-α and interleukin-6 may also been 
associated with hypertensive disorders in pregnancy.38  
Nutrients and Maternal Blood Pressure  
As a whole, research determining the various independent causes of hypertensive 
disorders of pregnancy are not totally understood, and as such, the relationship 
between specific nutrient levels or intakes and maternal blood pressure remains 
uncertain. This is highlighted in a prospective observational cohort study by Oken et 
al. (2007),39 which examined the associations between gestational hypertension and, 
among others, calcium, omega-3 fatty acids, magnesium, folate, and vitamins C, D, 
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and E. Pregnant women included in the study were participants in Project Viva, with a 
final sample size of 1718 women. Women completed questionnaires and interviews to 
collect information related to maternal characteristics and dietary patterns. The study 
determined that compared with women maintaining a normal blood pressure 
throughout pregnancy, women with PE had a lower consumption of omega-3 fatty 
acids, vitamin C, E, folate, and magnesium, while women with gestational 
hypertension maintained higher dietary intakes of vitamins C, D, and E. However, the 
risk for PE or gestational hypertension was not reduced, despite intake levels of 
calcium or vitamin D. Furthermore, women only had a lower risk of PE with increased 
levels of omega-3 fatty acids and magnesium. That study is just one example of how 
specific nutrients may have independent associations with hypertensive disorders of 
pregnancy; and often, the relationships are not as expected.  
Calcium 
One of the first descriptions of the relationship between calcium and high blood 
pressure in pregnancy was due to the observation that pregnant, Guatemalan women 
who were considered poor, had a low prevalence of eclampsia (0.4%) compared to 
other developing countries (e.g. 12%, India), as well as developed countries (e.g. 
Japan, 15%).40 That population also maintained high levels of calcium consumption 
(1320 mg/day in urban settings) compared to the other countries (347 mg/day, India; 
368 mg/day, Japan). A staple food in the Guatemalan diet that contributed high 
amounts of calcium was maize tortillas, which were cooked and soaked in lime water 
(calcium hydroxide). Similarly, in Ethiopia, a diet consisting of the grain, teff, and 
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lime in meal preparation allowed for a daily consumption of ~1075 mg of calcium per 
day. Meanwhile, the prevalence of eclampsia in Ethiopia was 0.9%.40  
As research has progressed, calcium supplementation during pregnancy in 
populations with inadequate calcium levels41 has been associated with a lower risk for 
pregnancy complications such as maternal HTN, and adverse birth outcomes. A 
suggested mechanism is derived from the association between increased calcium 
intake and decreased parathyroid hormone (PTH). PTH plays a central role in calcium 
homeostasis and blood pressure regulation. Low levels of calcium signal the 
parathyroid glands to increase circulating PTH. Increased PTH increases 
vasoconstriction, which ultimately raises blood pressure and signals the kidneys to 
increase calcium reabsorption and phosphate excretion; as well as the stimulation of 
bone resorption to increase calcium levels.42,43 
Additional mechanisms to describe the relationship between calcium and 
maternal blood pressure may include the regulation of hormones in addition to PTH, 
such as calcitriol, a derivative of vitamin D, and calcitonin. High extracellular calcium 
stimulates the release of calcitonin,44 which is a hormone produced in the thyroid 
gland that opposes PTH and can function to increase vasodilation. Therefore, 
calcitonin has an inverse relationship with blood pressure. Calcitonin gene-related 
peptide (CGRP) is a member of the calcitonin family,45 and levels of CGRP 
significantly increase throughout pregnancy, before returning to pre-pregnancy levels 
post-delivery.46This is consistent with the inverse trajectory of maternal blood pressure 
in healthy individuals, which decreases until mid-pregnancy and returns to normal 
near delivery.6,7 Moreover, in a case-control study with pre-eclamptic women and 
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matched normotensive women, CGRP was significantly lower in women with pre-
eclampsia than controls between 21-29 weeks gestation (p<0.001).47 Hence, it is 
suggested that increased extracellular calcium, which stimulates calcitonin, results in 
vasodilation and decreased blood pressure. The reverse may also be true, in that 
decreased calcium and lower calcitonin levels allows for vasoconstriction and 
increased maternal blood pressure.  
Currently, it is recommended that pregnant women with low calcium intake 
supplement 1.5-2.0 grams of calcium daily, to decrease risk of HTN.3 However, while 
calcium supplementation during pregnancy in populations with inadequate calcium 
levels has been associated with a lower risk for maternal HTN,48 it remains uncertain 
whether calcium supplementation may benefit women with adequate calcium intake.49 
Vitamin D 
Vitamin D is a fat-soluble vitamin, which can be present in the body in inactive 
form (cholecalciferol). With UVB exposure through sunlight, inactive vitamin D can 
be metabolized by the liver to calcidiol and converted by the kidneys to the active 
form, calcitriol50 . In addition to endogenous sources, active vitamin D can be obtained 
through nutrient supplements and dietary sources such as fish, mushrooms, and 
fortified food products51 . For health promotion and disease prevention, adequate 
levels of vitamin D for the general population are currently considered to be a 
concentration of 75 nmol/L, while inadequate levels are < 50 nmol/L.52 In the United 
States, it is estimated that > 30% of pregnant women maintain inadequate levels of 
vitamin D,53 whereas only 1% of pregnant women in Tanzania are inadequate54 and 
96% in India.55  
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Research related to vitamin D that is of high quality and relatively reliable remains 
limited, specifically within pregnant populations.56,57 Therefore, adequate intakes and 
corresponding health impacts remain unclear.57 The consequences of a deficiency of 
vitamin D may include an infant born with low birth weight, an infant born small for 
gestational age,58 myopathy (muscle disease),59 and certain autoimmune diseases; 
although the extent to which vitamin D impacts diseases independent of calcium 
requires additional research60. During pregnancy, vitamin D has also been associated 
with a decreased risk for maternal high blood pressure56 and involvement in calcium 
maintenance homeostasis.61   
Research is conflicting on mechanisms by which vitamin D may influence 
maternal blood pressure.62,63 One mechanism includes the ability of vitamin D to 
stimulate calcium absorption, transport and removal across intestinal cells,64 though 
recent research indicates an inverse relationship between vitamin D and PTH.63 As 
previously mentioned, PTH plays a central role in the calcium metabolic pathway and 
blood pressure regulation, and decreased levels of vitamin D may increase PTH, 
thereby increasing vasoconstriction. In a cross-sectional study by Garcia et al. 
(2013),62 significant correlations in adjusted models were found between PTH and 
SBP (r = 0.146; P = 0.010) and DBP (r = 0.126; P = 0.026) and PTH and vitamin D 
status (r = −0.133; P = 0.019). However, associations between vitamin D status and 
blood pressure were insignificant. Similarly, Hemmingway et al. (2018), found that 
PTH decreased significantly in pregnant women with increasing vitamin D, 
(P < 0.001), however there were no significant associations between elevated PTH and 
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gestational hypertension or vitamin D deficiency and risk of gestational 
hypertension.65  
Sodium and Potassium  
The American Heart Association recommends the restriction of sodium (Na) to < 
1500 mg in the general population, and 2300 mg as the upper intake level to prevent 
adverse health outcomes.66 This is because high sodium intake has been associated 
with an increased risk for high blood pressure and cardiovascular disease in the 
general population.67-69  
One suggested mechanism linking sodium intake and increased blood pressure is 
related to the regulation of extracellular fluid volume. In healthy adults, a renal arterial 
pressure may signal the kidneys to either retain or excrete sodium in order to control 
BP, called pressure natriuresis. However, with high sodium intake, the function of 
hormones in the renin-angiotensin aldosterone system responding to sodium levels and 
blood pressure may be impaired and result in dysregulation of the extracellular fluid 
volume and concurrently vasoconstriction.70 Increased extracellular fluid volume and 
vasoconstriction may result in increased blood pressure.71 
One strategy that promotes a restriction of sodium is the dietary approaches to 
reduce hypertension (DASH) diet, which promotes increased fruits, vegetables, whole 
grains and the reduction of saturated fat and sodium.72 The DASH diet has been 
associated with a reduced risk for HTN, as well as decrease mean blood pressure in 
those with hypertension.73-75 
While sodium restriction has been a popular strategy to prevent or treat 
hypertensive disorders, research on sodium intake during pregnancy and the effects on 
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blood pressure has long been conflicting.76 Similarly, a low-sodium diet during 
pregnancy has not consistently been significantly associated with a decrease in risk for 
maternal HTN, nor is it recommended to limit intake during pregnancy.77 In the 
1960’s, for example, there was research to support that an increase in sodium intake to 
as much as 10 grams per day may be used to reduce blood pressure in pre-eclamptic 
patients.78 Later, in the 1990s, sodium intake was not associated with maternal BP, but 
was associated with significantly reduced intakes of energy, protein, carbohydrates, 
fat, Ca, Zn, Mg, Fe and cholesterol.79 More recently, a clinical study in Southeast Asia 
found that increased salinity of drinking water was associated with increased maternal 
blood pressure.80 On the other hand, a study by Inoue et al. (2016),81 found no 
significant associations between urinary salt excretion and maternal BP in Japan.  
Current research is also exploring the relationship between sodium and potassium 
(K), and the ratio that may be most effective for BP reduction.82 Potassium is an 
electrolyte that may influence sodium retention by signaling the kidneys, hormonal 
activation and influence the function of vascular smooth muscle.83 An analysis of 
NHANES data determined that higher sodium and lower potassium was associated 
with increased SBP in non-pregnant persons.84 In a study by Yilmaz et al. (2017),85 
pregnant women with pre-eclampsia in a low Na/K group had significantly lower 
mean SBP and DBP (mmHg) levels (148.2 ± 8.9, 92.3 ± 6.2) compared to the mean of 
the medium Na/K group (155.0 ± 9.1, 97.1 ± 9.5) or high Na/K (158.5 ± 12.2, 99.2 ± 
8.57) group; (p=0.024, p=0.0002, respectively). While these studies do support a 
significant association between a low Na/K ratio, further research is needed to 
determine the relationship with BP in healthy, pregnant populations.  
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 In summary, the effect of sodium restriction to decrease maternal BP and to 
prevent or treat hypertensive disorders during pregnancy is unclear. Further research is 
needed on the mechanisms by which sodium impacts blood pressure, specifically 
during pregnancy, as well as the impact of Potassium and various Na/K ratios.  
Additional Nutrient Supplementation 
Additional nutrients with limited research on their relationship with maternal 
HTN include essential fatty acids (EFAs), folate, magnesium, antioxidants 
(specifically vitamins E, C, and selenium), and zinc.  
EFAs - Increased essential fatty acids are associated with a greater gestational 
age and fewer preterm births.86-89 There is also emerging evidence that essential fatty 
acids play a role in decreasing placental dysfunction and inflammation and support 
fetal growth and neurological development. Although EFAs have been associated in 
animal studies with reduced the risk of maternal HTN and inflammatory markers 
possibly involved in the pathogenesis, research in human populations is limited.90,91  
Larger intervention studies in women have not found significant associations between 
EFA supplementation or intake and maternal HTN.92,93  
Folate – Homocysteine is an amino acid that is associated with cardiovascular 
disease,94 and has been associated with the risk for PE and vasoconstriction during 
pregnancy. It may also increase inflammation and contribute to endothelial 
dysfunction. Decreased folate concentrations may lead to elevated homocysteine 
levels, thereby resulting in maternal HTN. In non-pregnant women with folate 
deficiency, serum folate was inversely related to blood pressure.95 However, larger 
meta-analysis have highlighted the conflicting outcomes of the research, and 
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ultimately determined no difference in maternal risk for hypertensive disorders of 
pregnancy as a result of folate levels.96  
Magnesium - Although magnesium intake has been associated with reduced 
instances of PE, in a double-blind interventional study with ~200 pregnant women, 
magnesium supplementation was not significantly associated with maternal blood 
pressure.97 This is consistent with systematic reviews concluding that there is 
insufficient evidence to recommend maternal magnesium supplementation to prevent 
maternal HTN.98 The underlying mechanism for how magnesium may influence 
maternal blood pressure, also remains unclear. 
Antioxidants - Antioxidants have been associated with endothelial dysfunction, 
which has been suggested as a mechanism for maternal HTN. However, studies of the 
supplementation of vitamins C or E or selenium, have found weak or insignificant 
association with decreasing risk for PE or hypertensive disorders of pregnancy.99-102  
Zinc - While increased zinc has been associated with decreased oxidation,103 it is 
not recommended during pregnancy as a strategy to decrease the risk for maternal high 
blood pressure. Much of the research related to zinc and maternal blood pressure is 
inconclusive and largely conflicting.104  
Dietary Patterns  
There is limited research related to overall dietary patterns during pregnancy and 
maternal BP. One well-known dietary pattern is the Mediterranean diet, which 
emphasizes whole grains, plant-based foods such as fruits and vegetables, as well as 
the incorporation of olive oil and fish.105 The Mediterranean diet has been associated 
with decreased risk for HTN and cardiovascular disease in the general population,106 
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although low adherence to a Mediterranean-style dietary pattern was not significantly 
associated with PE or gestation hypertension in an observational study with 3,187 
pregnant women.107 In addition, diet quality as assessed in Project Viva’s Alternate 
Healthy Eating Index, was not associated with the risk for PE.108 However, in a study 
with nearly 30,000 Norwegian, pregnant women,109 dietary patterns emphasizing 
vegetables, plant foods and vegetable oils were associated with a decreased risk for 
PE. In the same study, an increased risk for PE was found in dietary patterns 
emphasizing processed meat, salty snacks, and sweet drinks.  
Maternal Blood Pressure and Newborn Birth Weight  
A birth outcome that may result from maternal HTN is an infant born with a 
low birth weight (LBW). Regardless of whether the infant was born at term (~37 
weeks gestation) or preterm, LBW is defined as newborn weight < 2500 grams 
(~5.5lbs). In 2014, the World Health Organization (WHO) reported that nearly 15% 
newborns worldwide are born with LBW.110 While some of the known risk factors for 
LBW are non-modifiable, such as maternal age and ethnicity,111 modifiable risk 
factors include infections, drug use, anemia, low maternal BMI and chronic maternal 
undernutrition.111,112 Among other things, an infant born with LBW has increased risk 
for coronary heart disease,113 impaired cognitive function,114 and non-insulin 
dependent diabetes.115 As a result, in 2016, WHO set a goal of a 30% reduction in 
newborns with LBW by the year 2025.116   
The prevalence of low-birth weight in Sub-Saharan Africa, an area including 
Ghana, is about 13%.110 To determine risk factors related to LBW in Ghana, a 
retrospective cohort study with 6,900 participants by Kayode et al. (2014),117 was 
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conducted, while controlling for the context of the community in which the mothers 
resided. Living in a rural setting increased the risk of LBW (OR 1.43, 95% CI: 1.01–
2.01; p < 0.05), as well as living in a community with a high poverty level (OR 2.16, 
95% CI: 1.29–3.61; p < 0.01). However, access to community health care services was 
not significantly associated with the risk of LBW (OR 1.28, 95% CI: 0.87–1.87; p > 
0.05). 
The Generation R study is a population-based prospective cohort study, 
conducted in the Netherlands with > 8,800 pregnant women.118 In an analysis of the 
associations between blood pressure, fetal growth risk, and the risk of adverse birth 
outcomes, a change in SBP from the second trimester to third trimester was 
significantly associated with an increased risk for LBW (OR 1.25, 95% CI: 1.12 - 
1.40). Furthermore, a change in DBP from the second to third increased the risk (OR 
1.49, 95% CI: 1.34 – 1.67), as well as a change between the first and third trimester. 
This study also found that women with gestational hypertension gave birth to infants 
with lower birth weights () = -89 grams, 95% CI: -137 to - 41, p < 0.01, respectively), 
and odds of LBW at 1.85 (95% CI: 1.15 – 2.97) compared to women with normal 
blood pressure during pregnancy.  
Maternal HTN has been associated with an increased risk for adverse birth 
outcomes primarily in high-income populations. Aside from LBW, outcomes of 
maternal HTN include increased risk of preterm,118-120 an infant born small for 
gestational (SGA),120,121 with a small head circumference,118 or still birth.119,121 While 
the underlying mechanisms for how maternal BP contributes to birth outcomes 
remains unclear, mechanisms may involve maternal HTN leading to placental 
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dysfunction, specifically reduced placental perfusion, and inflammation. Inflammation 
may lead to fetal hypoxia that may inhibit fetal growth, as well as reduce gestational 
age, and other pregnancy complications.86,122,123 Alternatively, one hypothesis is that 
maternal HTN is actually a consequence of fetal growth restriction. This is based on 
the idea that to compensate for reduced placental perfusion and decreased birth 
weight, maternal blood pressure increases.124  
Conclusion 
As a whole, the etiology and underlying mechanisms of maternal high blood 
pressure are not well understood, further complicated by the nature of individual 
hypertensive disorders of pregnancy. To avoid risks associated with hypertensive 
medication, nutrient supplementation to manage maternal blood pressure is of 
increasing interest. However, research related to the effect of nutrient supplementation 
or dietary patterns on maternal blood pressure is conflicting. Limitations to current 
research include inconsistencies in the definitions and specifications of hypertensive 
disorders, as well as the trimester and duration in which the supplement was being 
administered. Furthermore, future research is needed to determine the most effective 
dosages and underlying mechanisms of nutrient supplements to influence blood 
pressure; specifically, for calcium, vitamin D, and sodium. Maternal blood pressure is 
also associated with adverse birth outcomes, such as an infant born with a low birth 
weight, which is associated with long-term chronic disease. Future research is needed 
to elucidate the pathology of low birth weight caused by maternal high blood pressure. 
In conclusion, maternal high blood pressure is a major challenge to public health 
worldwide, and even more-so in developing countries. 
 





EXTENDED METHODOLOGY  
Study Setting  
 The iLiNS study was conducted in southern Ghana, in an area north of Accra, 
within various semi-urban communities. These communities are primarily subsistence 
farmers or petty traders, with access to electricity and a public supply of water. Ghana 
is considered to be a low-middle income country, and residents of these specific 
communities are not poor or rich by Ghanaian standards. Staple foods included in the 
regular diet include maize, cassava, rice, fish, and leafy vegetables.  
Study Design  
This is a secondary data analysis of the International Lipid-Based Nutrient 
Supplements (iLiNS) Project. iLiNS is a partially double-blind, parallel, randomized 
controlled trial. The research team recruited pregnant women attending select prenatal 
clinics, to determine the effects of nutrient supplements during pregnancy and the first 
eighteen months of the newborn’s early childhood. For this analysis, data collected 
from early pregnancy through birth will be used. A prenatal lipid-based nutrient 
supplement (LNS) is a paste designed to be mixed with local food to increase the 
nutrient and energy content for enrolled Ghanaian women during pregnancy and 
lactation. Multiple micronutrients (MMN) and LNS supplements followed 
formulations for United Nations Micronutrient Preparation (UNIMAP) previously 
used in pilot programs among pregnant women.125 Nutriset S.A.S. (Malaunay, France)  
produced the LNS in 20g sachets and Dutch State Mines (DSM) South Africa 
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(Kaiseraugst, Switzerland) produced the capsules of the iron and folic acid (IFA) and 
MMN supplements. A more detailed description of the study population and methods 
have previously been described.126 
The iLiNS study protocol was approved by the institutional review boards at 
the University of California, Davis; the Noguchi Memorial Institute for Medical 
Research, University of Ghana; and the Ghana Health Service. 
Participants 
 Eligibility for this study was specific to women attending prenatal clinics, and 
recruited between December 2009 through December 2011, an age of at least 18 years 
old, and a gestational age of ≤ 20 weeks. Reasons for exclusion included a test result 
that was HIV positive at baseline, a gestational age > 20 weeks, residence > 20 km 
outside of southern Ghana, history of peanut or milk allergies, severe illness, or the 
intention to move within two years. Participants consented to screen for eligibility, and 
if eligible, fieldworkers collected anthropometrics and baseline lab values.   
Randomization and Blinding 
 A randomization scheme was designed by a study statistician. Each woman 
was randomized into either the IFA, MMN, or LNS group. The major steps of the 
randomization process are as follows: 
• Computer-generation (SAS version 9.3) randomized women after baseline 
assessments into one of three groups.  
• A total of 1,320 envelopes (one for each participant), were divided into three 
groups, and organized into blocks of nine. A block of nine envelopes contained 
three envelopes for IFA, three for MMN, and three for LNS. 
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• A nurse shuffled one block of nine envelopes, and the participant chose one 
envelope to determine group allocation. 
To ensure blinding, an independent party from the research team color-coded 
supplement capsules of the IFA and MMN groups to blind investigators, fieldworkers, 
and participants. This allowed for sole identification of the capsule to be by color and 
not supplement content. During follow-up visits, fieldworkers received the color-
coded supplement allocations for the participants from the field supervisor. Since LNS 
was not a capsule, fieldworkers and participants could not be blinded from 
distinguishing between LNS and IFA or MMN. Fieldworkers were not aware of the 
group allocations, and data analysts were blinded until the completion of preliminary 
analyses.  
Procedures 
At enrollment, the research group distributed surveys to participants and 
collected demographic characteristics and lab data. The research group collected lab 
data again at 36 weeks gestation and newborn anthropometric measurements at 
delivery.  
At enrollment, fieldworkers distributed a two week supply of the assigned 
supplement along with instructions on consumption methods. At bi-weekly, in-home 
follow-ups with each participant, data on supplement adherence and morbidity, as well 
as any remaining supplement were collected. Fieldworkers visited the home or 
hospital at delivery to collect anthropometric measurements of newborns. For 91% of 
infants, measurements were recorded within 48hrs of birth. Measurements for 9% of 
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infants were not available after 48hrs, and so measurements were collected between 3-
14 days after birth.  
Primary Outcomes and Definitions  
Our primary outcomes to determine the effect of a nutrition supplement on 
maternal hypertension are mean SBP and mean DBP at enrollment and 36 weeks 
gestation. Our primary outcome to determine the association between maternal HTN 
and birth weight is mean newborn birth weight. High SBP was defined as ≥130 mmHg 
and high DBP as ≥80 mmHg. Consistent with the iLiNS study, for age- and sex-
standardization of blood pressure and weight, the WHO 2006 multi-center growth 
standard was used.127 If the baby was measured within 48 hours, birth weight is 
reported in grams. If after 48 hours, adjustments for weight following the main iLiNS 
study were employed. 
Statistical Analysis - Effect of LNS on Maternal HTN 
In this randomized study design, quantifying the as-treated effect of LNS on 
maternal hypertension was of primary interest. During the study, IFA and MMN 
capsules were unintentionally mislabeled, causing 92 participants in the IFA group 
and 85 participants in the MMN group to receive the incorrect supplement. Therefore, 
this analysis used the supplement treatment assignment actually received and not the 
treatment originally assigned. A total of 86 women not-exposed in the LNS group, as 
well as the mixed-exposure women in the IFA or MMN groups were excluded.   
The main iLiNS trail included a total sample size of 1,057 (excluding women 
pregnant during mixed exposure), where IFA = 349, MMN = 354, and LNS = 354. 
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Our sample size for each group is consistent with the main iLiNS trial and included 
the total sample size of 1,057. All tests were two-sided, at a 5% level of significance. 
Residuals were assessed for normality using a Shapiro-Wilk statistic. Pre-
pregnancy body mass index (BMI), C-reactive protein (CRP) at enrollment and α1-
acid glycoprotein (AGP) at enrollment were not normally distributed and were 
logarithmically transformed for analysis. The heteroscedasticity assumption was also 
examined through the plots and no outliers were identified through visual 
identification in histograms or scatterplots.  
Variables that were possible confounders and had a statistically significant 
association with the outcome (p<0.1 in univariate models) were included in an 
adjusted regression model. The following potential confounders were considered: pre-
pregnancy BMI, gestational age, maternal age, maternal education, assets index, food 
insecurity score, hemoglobin, parity, history of hypertension, maternal height, CRP, 
AGP,  a positive malaria test, season at maternal enrollment (dry vs wet), marital 
status, and offspring sex reported at birth.  
To avoid collinearity, variables were considered in the separate logistic 
regression models to assess the effect of the intervention on maternal blood pressure. 
If a variable was significantly associated with the effect of the intervention, logistic 
regression was used to determine if the effect of LNS on blood pressure was 
significantly different between groups. The null-hypothesis was rejected at the 0.05 
level.  
Linear regression was used to estimate the study intervention effects on blood 
pressure.  For the continuous outcomes, the difference between the three group means 
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was tested with ANOVA and ANCOVA models. If the null-hypothesis was rejected at 
the 0.05 level, post-hoc pairwise comparisons across the three intervention groups was 
tested using the Benjamini-Hochberg procedure to adjust for multiple comparisons.128 
Due to the number of participants exposed to the incorrect supplement, a 
sensitivity analysis was conducted to determine if the exclusion of those women 
influenced the results. The analyses determining the effect of LNS on maternal HTN 
was repeated with all participants included.  
Statistical Analysis - Association between maternal blood pressure and birth weight  
We evaluated normality of the residuals using a Shapiro-Wilk statistic. The 
distributions of pre-pregnancy BMI, CRP and AGP at enrollment had deviations from 
normality, and were logarithmically transformed for analysis. The heteroscedasticity 
assumption was examined through the residual versus fit plot. A scatterplot between 
the independent and dependent variables was visually examined to check that the 
relationship between the predictor and response was linear. No outliers were visually 
identified through histograms or scatterplots.   
The covariates recorded at enrollment that had a statistically significant 
association with the outcome (p<0.1) were included in adjusted regression models. 
The covariates recorded at enrollment that were considered for inclusion in an 
adjusted model are as follows: Pre-pregnancy BMI, gestational age, maternal age, 
maternal education, assets index, food insecurity score, parity, season at maternal 
enrollment (dry vs wet), hemoglobin, marital status, history of hypertension, offspring 
sex, maternal height, CRP, AGP, positive Malaria test, and treatment group.  
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For continuous predictors, collinearity was checked by running models with 
covariates and an examination of variance inflation factors (VIF). VIF above 10 was 
considered problematic, however, there were no variables that exceeded a VIF of two. 
Therefore, there was no evidence of collinearity and all variables significantly 
associated with the outcome were included in adjusted models.  
Continuous variables were analyzed with linear regression if they were 
determined to have a statistically significant association with the outcome. Multiple 
linear regression models were used to determine the association between systolic and 
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